BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazzarelli C, Cannon MD, Belli LS, Agarwal K. Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything. Journal of Hepatology 2018;68:217-8. [DOI: 10.1016/j.jhep.2017.08.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
2 Wuerth K, Magel T, Conway B. Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C. Future Virology 2019;14:715-27. [DOI: 10.2217/fvl-2019-0104] [Reference Citation Analysis]
3 Tse CS, Yang JD, Mousa OY, Nelson KM, Pungpapong S, Keaveny A, Aqel BA, Vargas H, Dickson RC, Watt K, Gores GJ, Roberts LR, Leise MD. Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplant Direct 2021;7:e635. [PMID: 33324740 DOI: 10.1097/TXD.0000000000001049] [Reference Citation Analysis]
4 Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24(24): 2582-2595 [PMID: 29962815 DOI: 10.3748/wjg.v24.i24.2582] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]